U.S. Markets open in 3 hrs 20 mins
  • Crude Oil

    70.51
    -0.05 (-0.07%)
     
  • Gold

    1,768.40
    -9.80 (-0.55%)
     
  • Silver

    23.03
    +0.46 (+2.05%)
     
  • EUR/USD

    1.1696
    -0.0034 (-0.2924%)
     
  • 10-Yr Bond

    1.3360
    +0.0120 (+0.91%)
     
  • Vix

    20.87
    -3.49 (-14.33%)
     
  • GBP/USD

    1.3619
    -0.0045 (-0.3282%)
     
  • USD/JPY

    109.7800
    +0.5600 (+0.5127%)
     
  • BTC-USD

    42,363.55
    -1,791.08 (-4.06%)
     
  • CMC Crypto 200

    1,089.55
    +49.07 (+4.72%)
     
  • FTSE 100

    7,083.37
    +102.39 (+1.47%)
     
  • Nikkei 225

    29,639.40
    -200.31 (-0.67%)
     

Innovent Biologics - Incyte's Pemigatinib Application Under Review In China For Bile Duct Cancer

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • The National Medical Products Administration (NMPA) of China has accepted for review Innovent Biologics Inc's (OTC: IVBIY) marketing application seeking approval for pemigatinib for cholangiocarcinoma.

  • The FGFR1/2/3 inhibitor's application covers adults with previously treated, unresectable locally advanced, or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement.

  • Pemigatinib is a tyrosine kinase inhibitor discovered by Incyte Corporation (NASDAQ: INCY) and is licensed to Innovent for development and commercialization in Mainland China, Hong Kong, Macau, and Taiwan.

  • The submission is based on results from abridging study showing the overall response rate (ORR) of 37%, including four complete responses (3.7%) and 36 partial responses (33.3%).

  • The median duration of response (DOR) was 8.08 months, and the median progression-free survival (PFS) was 7.03 months.

  • Price Action: INCY shares are down 0.69% at $80.87 on the last check Friday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.